EXHIBIT "WITN3094001/22"

This is the exhibit marked "WITN3094001/1" referred to in the witness statement of Debra Anne Pollard dated 7 May 2019

(8)

FORWARD PLANNING AND MONITORING GROUP FOR ROLLOUT OF RECOMBINANT TREATMENT FOR ADULT HAEMOPHILIA PATIENTS

Decisions made at the meeting held on 9 February 2004, at the Department of Health, Skipton House, Elephant & Castle, London

Present:	Richard Gutowski	Department of Health
	Zubeda Seeda	Department of Health
	Frank Hill	UKHCDO
	Charles Hay	UKHCDO
	Sybil Hirsch	UKHCDO
	Rob Hollingsworth	UKHCDO
	Mick O'Donnell	West Midlands SCG
	David Kemsley	London SCG

The group (hereafter to be called "The Forward Planning and Monitoring Group for Rollout of Recombinant Treatment for Adult Haemophilia Patients") agreed that there was the need to provide a pragmatic solution to ensure the start of the rollout in this financial year.

The available funding will be targeted to the PCT of individual patients who are to be started on recombinant treatment in 2003-2004. This should be viewed as "pump priming" money. Because of the slippage etc. it would be necessary for:

1. Each Haemophilia Centre Director to determine the expected saving in 2003/04 on not purchasing plasma-derived product to the end of year.

2. This saving should be added to the allocated new money to the PCT and thus provide the total money available to purchase recombinant product for each eligible patient.

3. This sum needs to be concerted to the units of allocated recombinant product under the national contract and this should be purchased for each patient.

4. Any stock not used would be carried into the next financial year for each patient. Allocations of new monies in 2004/2005 may reflect this end of year stock.

5. PCT's and commissioners will need to be invoiced for this purchase.

6. The Project Manager at HND will provide each Centre Director with their list of eligible patients with identifiers, allocated product and allocated new money.

7. Having calculated savings in year on existing SLA's, the available total finance for spending in 2003/2004 is that plus the new money.

8. This information will need to be communicated by the Centre Director to the purchasing consortium where this exists, otherwise to the patient's PCT if there is no consortium arrangement.

9. Guidance to PCT's/commissioners will be that this money in 2003/2004 is to purchase the maximum amount of the allocated recombinant rather than purchasing the precise amount for the patient's treatment needs in year.

10. The DoH will send out to each PCT/commissioners the allocation of new money for each eligible patient.

11. AUDIT OF PROCESS 2003-2004.
This is to be kept simple. The data to be provided from each Centre by patient identifier will be:

(i) Date patient started on recombinant product.
(ii) Financial saving in year on not purchasing plasma-derived product.
(iii) Quantities of allocated recombinant purchased.
(iv) Quantity of recombinant product available as carry over stock on 4 April 2004 (both at Centre and in patient's home).

Auditing in year 2 will need to be more complicated but we hope this will be based on the monthly returns to PCT's that most Centres already provide.

FUTURE MEETINGS
12. Forward Planning & Monitoring Group will meet on 26 April 2004 in the hope of finalising next year patient allocations. Audit data will therefore need to be submitted in early April to prevent delays.

13. The Group agreed to have greater finance representation at future meetings.

February 2004